Purpose To evaluate the feasibility, toxicity and efficacy of the combination regimen
consisting of gemcitabine-FDR infusion plus erlotinib, in ACP patients. Methods Forty-two …

Background Gemcitabine has been recognized as a standard chemotherapy in advanced
pancreas cancer (APC). We conducted a phase II study of a triple combination regimen …

Context The combination of gemcitabine and erlotinib is a standard first-line treatment for
unresectable, locally advanced or metastatic pancreatic cancer. We reviewed our single …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

Background: Pancreatic cancer remains a disease of high mortality and one of the most
frustrating, resistant solid neoplasms to treat. The aim of this study was to evaluate a …

304 Background: G (30-minute infusion) plus E improves survival in patients with APC
compared with G alone. In a recent phase III trial, G-FDR showed a trend to better OS …

Purpose Addition of either nab-paclitaxel or erlotinib to gemcitabine to treat advanced
pancreatic cancer has demonstrated overall survival benefit. This study was conducted to …

AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …

LBA4011 Background: Gemcitabine plus erlotinib (GE) is regarded as one standard of care
for patients (pts) with APC and CE as an all-oral regimen could be a feasible option in this …

Purpose This study evaluated safety and efficacy of chemotherapy (gemcitabine plus
capecitabine) plus bevacizumab/erlotinib in advanced pancreatic cancer because dual …